Augmented Reality-based Telerehabilitation Platform for Patients With Stroke
Launched by STANFORD UNIVERSITY · Apr 30, 2025
Trial Information
Current as of August 20, 2025
Not yet recruiting
Keywords
ClinConnect Summary
The clinical trial titled "Augmented Reality-based Telerehabilitation Platform for Patients With Stroke" is exploring a new way to help stroke patients recover using augmented reality (AR) technology. This study aims to see if using an AR program can effectively assist in rehabilitation and if it can be assessed using a specific test called the Fugl-Meyer Assessment for the upper body. The trial is not yet recruiting participants.
To be considered for this study, participants need to be at least 18 years old, have had a stroke at least three months prior, and have some difficulties using their arm or hand, as measured by a specific scoring system. They should also be able to use the AR device on their own or with some help and be comfortable following instructions in English. However, people with certain conditions, such as significant vision problems or specific medical devices like pacemakers, cannot participate. If eligible, participants can expect to engage with innovative technology designed to support their recovery journey in a unique way.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. 18 years or older
- • 2. ≥3 months post ischemic or hemorrhagic stroke
- • 3. Upper extremity deficit with an FMA-UE score between 20-50
- • 4. Able to operate the AR device independently or with the help of a caregiver
- • 5. Sufficiently proficient in the English language to follow instructions from Reia
- Exclusion Criteria:
- • 1. History of developmental, neurological or psychological impairment leading to functional disability
- • 2. Vision or visual field impairment that interferes with the use of the AR headset
- • 3. Severe photosensitivity that makes use of the AR headset uncomfortable
- • 4. History of visually provoked seizures
- • 5. Hearing aids
- • 6. Cardiac pacemaker
- • 7. Implantable cardioverter-defibrillator (ICD)
About Stanford University
Stanford University is a prestigious academic institution renowned for its cutting-edge research and innovation in healthcare and medicine. As a clinical trial sponsor, Stanford leverages its extensive resources, including a collaborative network of world-class researchers and state-of-the-art facilities, to advance medical knowledge and improve patient care. The university is committed to conducting rigorous, ethical research that adheres to the highest standards of scientific integrity, fostering an environment where groundbreaking discoveries can translate into effective clinical applications. Through its clinical trials, Stanford aims to address critical health challenges and contribute to the development of novel therapies and treatment strategies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Stanford, California, United States
Patients applied
Trial Officials
Maarten Lansberg, MD, PhD
Principal Investigator
Stanford University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported